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 2 
Abstract 43 
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system characterized by 44 
adaptive and innate immune system dysregulation.  Recent work has revealed moderate 45 
alteration of gut microbial communities in subjects with MS and in experimental, induced 46 
models. However, a mechanistic understanding linking the observed changes in the microbiota 47 
and the presence of the disease is still missing. Chloroform-resistant, spore-forming bacteria 48 
have been shown to exhibit immunomodulatory properties in vitro and in vivo, but they have not 49 
yet been characterized in the context of human disease. This study addresses the community 50 
composition and immune function of this bacterial fraction in MS. We identify MS-associated 51 
spore-forming taxa and show that their presence correlates with impaired differentiation of IL-10 52 
secreting, regulatory T lymphocytes in-vitro. Colonization of antibiotic-treated mice with spore-53 
forming bacteria allowed us to identify some bacterial taxa favoring IL-10
+
 lymphocyte 54 
differentiation and others inducing differentiation of pro-inflammatory, IFN+ T lymphocytes. 55 
However, when fed into antibiotic-treated mice, both MS and control derived spore-forming 56 
bacteria were able to induce immunoregulatory responses.  57 
Our analysis also identified Akkermansia muciniphila as a key organism that may interact either 58 
directly or indirectly with spore-forming bacteria to exacerbate the inflammatory effects of MS-59 
associated gut microbiota. Thus, changes in the spore-forming fraction may influence T 60 
lymphocyte-mediated inflammation in MS. This experimental approach of isolating a subset of 61 
microbiota based on its functional characteristics may be useful to investigate other microbial 62 
fractions at greater depth. 63 
 64 
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Importance:  66 
Despite the rapid emergence of microbiome related studies in human diseases, few go beyond a 67 
simple description of relative taxa levels in a select group of patients. Our study integrates 68 
computational analysis with in vitro and in vivo exploration of inflammatory properties of both 69 
complete microbial communities and individual taxa, revealing novel functional associations. 70 
We specifically show that while small differences exist between the microbiomes of MS patients 71 
and healthy subjects, these differences are exacerbated in the chloroform resistant fraction. We 72 
further demonstrate that, when purified from MS patients, this fraction is associated with 73 
impaired immunomodulatory responses in vitro. 74 
  75 
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Introduction 76 
 77 
The human gut microbiota is emerging as a major immune regulator in health and disease, 78 
particularly in relation to autoimmune disorders. Most human microbiota studies to date have 79 
been based on unbiased exploration of complete microbial communities. However, limited 80 
sequencing depth, combined with high community richness and natural sample heterogeneity, 81 
might hinder the discovery of physiologically relevant taxonomical differences. Thus, targeted 82 
studies of specific microbial populations with defined characteristics may serve as a 83 
complementary approach to investigate disease-associated changes in gut microbiome.  84 
 85 
Spore-forming bacteria constitute a subset of Gram-positive bacteria that are resistant to 3% 86 
chloroform treatment (1, 2). Both human and mouse spore-forming bacteria have 87 
immunoregulatory functions (3, 4). Mouse spore-forming bacteria include segmented 88 
filamentous bacteria and Clostridia species, which have been shown to induce gut T helper 89 
lymphocyte responses (3, 5). More recently, human spore-forming bacteria from a healthy 90 
subject were also reported to induce Tregs in vitro and in gnotobiotic mice (4). However, 91 
whether the composition and functions of spore-forming bacteria are altered in immune mediated 92 
diseases is unknown. 93 
 94 
Multiple sclerosis (MS) is a chronic disease of the central nervous system, characterized by 95 
autoimmune destruction of myelin. MS pathogenesis is in part mediated by effector T 96 
lymphocytes, and counterbalanced by Tregs, that limit the autoimmune damage inflicted by the 97 
former population (6, 7) and potentially promote remyelination (8). Recent studies, including our 98 
own, associated MS with moderate changes in the relative amounts of gut microbiota that 99 
exacerbate T lymphocyte-mediated inflammation in vitro and in vivo by stimulating pro-100 
inflammatory IFN+ Th1 and inhibiting IL-10+ regulatory T lymphocytes (9, 10).  101 
 102 
We hypothesized that these MS-associated changes in gut microbial communities may involve 103 
spore-forming bacteria thus altering its overall immunoregulatory properties. To address this 104 
hypothesis, we isolated spore-forming bacteria from untreated patients with relapsing-remitting 105 
MS (RRMS) and matched controls and analyzed their community composition and 106 
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immunoregulatory functions in vitro and in the experimental autoimmune encephalomyelitis 107 
(EAE) mouse model.  108 
 109 
 110 
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Results 112 
 113 
MS-associated differences in microbial community composition are more evident in the 114 
spore-forming fraction 115 
We isolated the spore-forming bacterial fraction from stool samples of 25 untreated MS patients 116 
and 24 controls and tested their relative abundance by amplicon sequencing of 16S rRNA V4 117 
gene sequencing. This analysis revealed no differences in community richness between patients 118 
and controls (Chao1 metric of alpha diversity, Fig. 1A). However, a focused analysis on the 119 
spore-forming fraction increased sample variability both within and between groups (Fig. 1B) 120 
possibly by reducing the number of taxa of interest and thus amplifying the differences in their 121 
relative abundances (Fig. 1A, 1C).  122 
 123 
Spore-forming bacteria showed notable differences in taxonomical composition between cases 124 
and controls, with 22.43% (135 out of 602 total) OTUs significantly different (p=0.05, negative 125 
binomial Wald test, Benjamini-Hochberg correction) (Fig. 1D and Suppl. Table 1). These 126 
taxonomical differences were also noticeable at the class level in which Bacilli were significantly 127 
overrepresented in controls (Fig. 1E), and Clostridia, including Clostridium perfringens were 128 
significantly overrepresented in MS patients (Fig. 1F and Suppl. Fig. S1).  129 
 130 
Spore-forming bacteria from MS patients fail to induce anti-inflammatory T lymphocytes 131 
in vitro 132 
To investigate whether MS-associated differences in community composition of spore-forming 133 
bacteria were sufficient to alter the immune functions of primary blood mononuclear cells 134 
(PBMCs) from healthy human donors, we exposed human PBMCs to extracts of spore-forming 135 
bacteria isolated either from unrelated controls or from MS patients and used flow cytometry to 136 
evaluate T lymphocyte differentiation under different polarizing conditions (18-20). A 137 
comparison of the PBMC response to extracts of spore-forming bacteria from controls or from 138 
MS patients identified lower conversion into CD4+FoxP3+ Tregs (Fig. 2 A, C), including IL-10 139 
expressing Treg population (Fig. 2 B, D) in the PBMCs exposed to the MS-derived spore-140 
forming bacteria. These data suggest that spore-forming bacteria from MS patients are 141 
significantly less effective at inducing Treg differentiation. Of note, the small population of 142 
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 7 
Tregs that still differentiated in response to MS bacteria, retained their suppressive capacities in 143 
vitro (Fig. 2E), thereby indicating that this was a functionally active population. Interestingly, the 144 
percentage of IL-10+ Tregs induced by extracts of spore-forming bacteria positively correlated 145 
with the relative abundance of Bacilli and negatively correlated with the relative abundance of 146 
Clostridia (Fig. 2 F, expressed as Clostridia-Bacilli difference). Thus, the community 147 
composition of spore-forming bacteria (i.e. high Clostridia, low Bacilli) associated with MS was 148 
also correlated with an inhibition of their respective immunoregulatory functions.  149 
 150 
Gnotobiotic mouse models reveal associations between individual bacterial taxa and T 151 
lymphocyte responses 152 
To determine whether the MS-associated reduction in the ability of spore-forming bacteria to 153 
stimulate Treg differentiation was physiologically significant, we colonized a group of female 154 
antibiotic-treated mice (21) with spore-forming bacteria from either controls (n=2) or MS 155 
subjects (n=2) and measured the course and severity of EAE. We observed a significant 156 
reduction in disease severity in all mice whose GI tracts were reconstituted with spore-forming 157 
bacteria. However, this reduction was independent of whether the spore-forming fraction was 158 
isolated from MS or controls (Fig. 3 A). This indicated that while MS-derived spore-forming 159 
bacteria could be functionally distinguished in vitro, these differences were not sufficient to 160 
induce a phenotype in vivo in our experimental setting.  161 
 162 
We next analyzed whether spore-forming bacteria regulated T lymphocyte responses in vivo. To 163 
this end we colonized antibiotic-treated mice with spore-forming bacteria from 3 controls and 3 164 
MS patients and analyzed the resulting changes in bacterial composition and T lymphocyte 165 
differentiation. Principal coordinate analysis (PCoA) of the beta diversity of gut microbiota 166 
separated SPF mice from antibiotic-treated and colonized (i.e. gnotobiotic) mice. While no major 167 
shifts in community composition based on disease state of the donor were observed (Fig. 3B), 168 
multiple microbial taxa were differentially abundant (Fig. 3C, Suppl. Tables 2, 3), including an 169 
increase in Akkermansia (3 OTUs corresponding to A. muciniphila; Suppl. Table 3) in mice 170 
colonized with spore-forming bacteria from MS patients.  171 
 172 
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 8 
Further investigation identified individual taxa that were classified as either pro-inflammatory or 173 
anti-inflammatory- based on the correlation between their relative abundance in mouse stool 174 
samples and their ability to alter differentiation of IFN+ Th1 or IL-10+ regulatory lymphocytes 175 
from either spleen or mesenteric lymph nodes (MLN) in vitro (Fig. 3D, 3E). The pro-176 
inflammatory category (Fig. 3D, red rectangle) included taxa significantly increased in mice 177 
colonized with spore-forming bacteria from MS patients compared to controls (highlighted in 178 
red), while the anti-inflammatory category (mostly evident in splenocytes; blue rectangle) 179 
contained taxa significantly reduced in mice colonized with spore-forming bacteria from MS 180 
patients (highlighted in blue).  181 
 182 
The increase in Akkermansia muciniphila, a non-spore-forming bacteria, in gnotobiotic mice 183 
colonized with spore-forming bacteria from MS patients led to the hypothesis that spore-forming 184 
bacteria may regulate Akkermansia levels. The correlation between spore-forming community 185 
composition and relative abundance of Akkermansia is shown in Fig. 4A. The increase in 186 
Akkermansia was present not only in the mice colonized with spore-forming bacteria from MS 187 
donors, but also in MS donors themselves (p = 1.5E
-09
, negative binomial Wald test) (Fig. 4B). 188 
Of interest, we and others (9, 10) recently reported the increased abundance of Akkermansia in 189 
untreated MS patients and identified this bacterium as sufficient for driving T lymphocyte 190 
differentiation into the pro-inflammatory IFN+ Th1 phenotype in-vitro (10). Consistent with 191 
this result, we also observed a significant positive correlation between the relative abundance of 192 
Akkermansia and IFN+ Th1 lymphocyte differentiation (Fig. 4C) in gnotobiotic mice. While 193 
other taxa also correlated with Akkermansia levels and T lymphocyte differentiation (Fig. 4D) 194 
our data suggest that the observed immunological effects may be at least partially mediated by 195 
Akkermansia.  196 
 197 
 198 
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Discussion 200 
The spore-forming fraction of gut bacteria has been associated with immunoregulatory properties 201 
(4). Here we examined the structural composition and immunological effects of the spore-202 
forming fraction of gut microbiota from subjects with MS compared to controls. MS-associated 203 
differences in bacterial community composition were correlated with impaired anti-inflammatory 204 
functions, as evidenced by a reduction in their ability to drive T lymphocyte differentiation into 205 
IL-10+ Tregs in vitro.  Meanwhile, colonizing antibiotic-treated mice with spore-forming 206 
bacteria allowed us to identify specific taxa correlated with T lymphocyte differentiation into 207 
IFN+ and IL-10+ subtypes in vivo.  208 
 209 
Our results contribute to the evidence supporting the immunoregulatory functions of spore-210 
forming bacteria and show that these functions may be compromised in the context of 211 
autoimmunity. Previous studies on spore-forming bacteria had been conducted by isolating this 212 
fraction from a single healthy donor (4, 22). This approach allowed focusing on donor-specific 213 
bacterial strains, but provided limited information about the “baseline” composition and 214 
variability of this bacterial community in healthy humans. Here we used multiple healthy control 215 
donors to establish the baseline community composition of spore-forming bacteria, and 216 
compared these healthy profiles with those from patients with MS. 217 
 218 
Our data corroborate previous findings that spore-forming bacteria, almost exclusively belonging 219 
to the phylum Firmicutes, and classes Clostridia and Bacilli, induce anti-inflammatory T 220 
lymphocytes in vitro and protect from autoimmune inflammation in vivo (4, 5). We also show 221 
that the taxonomical distribution and immunoregulatory functions of spore-forming bacteria are 222 
altered in MS patients. While were able to show that these differences have functional 223 
consequences in-vitro, they were not sufficient to alter the course of EAE using antibiotic treated 224 
mice. One possible explanation for this counterintuitive finding is that since our mice were 225 
treated with antibiotics, they were not completely germ-free prior to colonization. As a 226 
consequence, unexpected interactions among antibiotic resistant communities and the spore-227 
forming fraction may have influenced the course of EAE. We recognize that using GF mice for 228 
these experiments could address some of these concerns. However, raising GF animals is still a 229 
highly specialized enterprise only available at select institutions. Further studies of gene 230 
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expression and metabolic output of spore-forming bacteria may provide therapeutic targets for 231 
regulating T lymphocyte responses to reduce autoimmune inflammation.  232 
 233 
The mechanisms by which spore-forming bacteria regulate host T lymphocyte differentiation 234 
remain to be discovered. Interestingly, an overlapping subset of bacterial taxa has recently been 235 
shown to inhibit host proteases, including cathepsins (23), which mediate adaptive immune 236 
responses by increasing Th17 (24) and limiting Treg differentiation (25). Although future studies 237 
are needed to establish this firmly, it is possible that spore-forming bacteria from controls, but 238 
not MS patients are able to stimulate Treg responses via cathepsin inhibition.  239 
 240 
Furthermore, healthy human spore-forming bacteria produce short chain fatty acids (SCFAs), 241 
including butyrate and acetate (26), which have been observed to stimulate Treg and inhibit Th1 242 
differentiation in vitro and in vivo (27), Mizuno 2017). Either pure butyrate or butyrate-243 
producing spore-forming bacteria from healthy humans have been shown to be sufficient Treg 244 
induction (28) in mice. Thus, human T lymphocyte differentiation into Tregs may be driven by a 245 
yet-undiscovered SCFA-synthesizing subset of spore-forming bacteria that is present in controls 246 
and absent in MS patients.  247 
 248 
Akkermansia muciniphila has previously been reported to be increased in MS patients compared 249 
to controls (9, 10, 29) and to have pro-inflammatory functions in vitro (10). In addition, 250 
Akkermansia has been shown to be resistant to broad-spectrum antibiotics (30), which in part 251 
may explain its persistence in mice colonized with spore-forming bacteria. The fact that high 252 
levels of Akkermansia were only seen in mice colonized with MS chloroform-resistant bacteria 253 
suggests that its population is normally regulated by commensals that are depleted in MS thus 254 
enabling Akkermansia overgrowth.  255 
 256 
Our finding that Clostridium perfringens is more abundant in the spore-forming bacterial fraction 257 
of MS patients is consistent with the association of C. perfringens with neuromyelitis optica 258 
(NMO), another demyelinating autoimmune disease (31-33). Putative mechanisms of C. 259 
perfringens-mediated autoimmunity include molecular mimicry between C. perfringens peptide 260 
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and a self-antigen in the human host (Varrin-Doyer 2012), and toxin-mediated increase in 261 
neuronal damage (32, 34). 262 
 263 
Due to the high variability of spore-forming bacteria across donors, mouse colonization with 264 
samples from additional donor pairs would be required to assess whether MS-associated 265 
reduction in regulatory T lymphocyte differentiation in vitro can be reliably reproduced in vivo. 266 
However, a major advantage of gnotobiotic mouse models is the ability to assess the association 267 
between immune responses and microbial abundance within experimental communities. The 268 
identification of additional taxa capable of inducing clear differentiation paths in immune cells 269 
will further contribute to our understanding their role in immune regulation. For example, our 270 
findings corroborate the anti-inflammatory functions of relatively unknown bacterial genera such 271 
as Anaeroplasma and Dehalobacterium in mouse models of inflammation (35, 36). 272 
 273 
In conclusion, we have investigated the immune functions of the spore-forming fraction of 274 
human gut microbiota in health and disease, using MS as a model of autoimmune inflammation. 275 
We identified novel bacterial taxa associated with MS as well as with T lymphocyte 276 
differentiation into both pro-inflammatory and regulatory phenotypes. Further studies of spore-277 
forming bacteria and other experimentally defined bacterial populations may reveal specific 278 
immunoregulatory mechanisms in MS and other diseases that may be targeted by therapeutic 279 
interventions.  280 
 281 
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Materials and Methods 287 
 288 
Isolation of spore-forming bacteria from human fecal samples  289 
Fecal samples were collected from 25 adult patients with RRMS that had not received disease-290 
modifying or steroid treatment for at least 3 months prior to the time of collection and 24 291 
subjects without MS or any other autoimmune disorder (controls) at the University of California, 292 
San Francisco (UCSF) (Table 1). The inclusion criteria specified no use of antibiotics or 293 
oncologic therapeutics in 3 months prior to the study. All individuals signed a written informed 294 
consent in accordance with the sampling procedure approved by the local Institutional Review 295 
Board. Samples were stored in collection vials (Fisher #NC9779954) at -80° C until bacterial 296 
isolation. 297 
 298 
Spore-forming bacteria were isolated based on their resistance to chloroform as described 299 
previously (Atarashi 2013). Briefly, total bacteria were isolated from stool samples by 300 
suspending ~0.5mg stool sample in 1.5ml PBS, passing it three times through a 70m cell 301 
strainer and washing twice with 1.5ml PBS by spinning at 8000rpm. The resulting suspension 302 
was diluted in 5ml PBS, mixed with chloroform to the final concentration of 3%, and incubated 303 
on a shaker for 1h at room temperature. After incubation, chloroform was removed from the 304 
solution by bubbling nitrogen (N2) gas for 30min. Chloroform-treated bacteria were then 305 
cultured on OxyPRAS Brucella Blood Agar plates (Oxyrase #P-BRU-BA) for 96 hours followed 306 
by Brucella Broth (Anaerobe Systems #AS-105) for 48 hours, and isolated for sequencing, in 307 
vitro experiments and in vivo experiments.  308 
 309 
16S rRNA amplicon sequencing and computational analysis 310 
DNA was extracted from mouse fecal or human chloroform-resistant bacterial culture samples 311 
using MoBio Power Fecal DNA extraction kit (MoBio #12830) according to manufacturer’s 312 
instructions. For each sample, PCR targeting the V4 region of the prokaryotic 16S rRNA gene 313 
was completed in triplicate using the 515/806 primer pair, and amplicons were sequenced on 314 
NextSeq at the Microbiome Profiling Services core facility at UCSF using the sequencing 315 
primers and procedures described in the Earth Microbiome Project standard protocol (11). 316 
 317 
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Analysis was performed using QIIME v1.9 as described (12). Essentially, amplicon sequences 318 
were quality-filtered and grouped to “species-level” OTUs via SortMeRNA method (13), using 319 
Greengenes v.13.8 97% dataset for closed reference. Sequences that did not match reference 320 
sequences in the Greengenes database were dropped from analysis. Taxonomy was assigned to 321 
the retained OTUs based on the Greengenes reference sequence, and the Greengenes tree was 322 
used for all downstream phylogenetic community comparisons. OTUs were filtered to retain 323 
only OTUs present in at least 5% of samples and covering at least 100 total reads. After filtering, 324 
samples were rarefied to 10000 sequences per sample. Alpha diversity was calculated using the 325 
Chao1 method (14). For analysis of beta diversity, pairwise distance matrices were generated 326 
using the phylogenetic metric unweighted UniFrac (15) and used for principal coordinate 327 
analysis (PCoA). For comparison of individual taxa, samples were not rarefied. Instead, OTU 328 
abundances were normalized using variance-stabilizing transformation and taxa distributions 329 
were compared using Wald negative binomial test from R software package DESeq2 as 330 
described previously (16, 17) with Benjamini-Hochberg correction for multiple comparisons. 331 
Linear correlations between bacterial taxa and lymphocyte proportions were computed after 332 
variance-stabilizing transformation of bacterial abundances (16).  333 
 334 
Mouse colonization with microbiota 335 
Female littermates 5 week old C57BL/6J mice (JAX #000664) were treated with 1% solution of 336 
Amphotericin B in drinking water for 3 days, followed by 2 weeks of a solution composed of 1% 337 
Amphotericin B, 1mg/ml ampicillin, 1mg/ml neomycin, 1mg/ml metronidazole and 0.5mg/ml 338 
vancomycin in drinking water. After 2 weeks, the drinking solution was replaced by sterile water 339 
and mice were gavaged with specific bacteria of interest at 2*10^8 CFU in 100ul per mouse 340 
every 2 days for 2 weeks (7 total gavages). Bacterial colonization was either followed by the 341 
induction of EAE or immunophenotyping of mesenteric and cervical lymph nodes.  342 
 343 
To induce EAE, mice were immunized in both flanks with 0.1ml MOG35-55 emulsion (1.5 344 
mg/ml) mixed with Complete Freud’s Adjuvant and killed Mycobacterium tuberculosis H37Ra 345 
(2mg/ml), followed by two 0.1ml intraperitoneal injections of pertussis toxin (2µg/ml) 346 
immediately and at 48h after MOG/CFA injections. Mice were scored daily in a blinded fashion 347 
for motor deficits as follows: 0, no deficit; 1, limp tail only; 2, limp tail and hind limb weakness; 348 
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3, complete hind limb paralysis; 4, complete hind limb paralysis and at least partial forelimb 349 
paralysis; 5, moribund.  350 
 351 
At the time of euthanasia, mouse mesenteric lymph nodes, and spleens were dissected and 352 
processed by grinding tissues through a 70µm cell strainer. Entire mesenteric and cervical lymph 353 
nodes and 10^7 splenocytes per mouse were stimulated for 4-5 hours with 20ng/ml PMA and 354 
1µg/ml ionomycin in presence of protein transport inhibitor (GolgiPlug, BD #51-2301KZ) and 355 
used immediately for immunophenotyping, while the remaining splenocytes were stored for in 356 
vitro bacterial stimulations.  357 
 358 
Bacterial stimulation of human immune cells  359 
Human peripheral blood mononuclear cells were isolated from healthy volunteers and stored at -360 
80° C in cryovials at 10^7 cells/ml concentration in FBS containing 10% DMSO. Before plating, 361 
cells were washed in PBS twice, re-counted, and plated at 10^6 cells/ml concentration in RPMI 362 
media supplemented with 10% FBS and 1% penicillin/streptomycin/glutamine. Cells were 363 
stimulated for 3 days as described previously (18) with anti-human CD3 (BD #555336, 0.3 364 
µg/ml), anti-human CD28 (BD #555725, 2 µg/ml) and recombinant human TGF-1 (R&D 365 
#240B002, 2.5ng/ml). 366 
 367 
Bacteria isolated from human chloroform-resistant cultures were resuspended in PBS 368 
supplemented with protease inhibitor (Roche #4693159001) and phosphatase inhibitor (Roche 369 
#4906845001), heat-inactivated at 65° C for 1h and sonicated for 10min as described previously 370 
(19). Protein concentration in the resulting suspension was measured using the Pierce BCA 371 
protein assay kit (Thermo Scientific #23227). Bacterial extracts were added to PBMCs at 1µg/ml 372 
1h after plating as described previously (20). PBS with the same protease inhibitor and 373 
phosphatase inhibitor was added as the no-bacteria control. Each human in vitro experiment 374 
contained at least 6 independent donor bacterial samples and was repeated at least twice. 375 
 376 
Immunostaining, flow cytometry and FACS of human immune cells  377 
Human PBMCs were immunostained using standard protocols. Live/dead cell gating was 378 
achieved using Live/Dead Fixable Aqua kit (ThermoFisher #L34957). FoxP3/transcription factor 379 
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staining buffer set (eBioscience #00-5523-00) was used for staining of intracellular and 380 
intranuclear cytokines. The following antibodies were used for human PBMC staining: anti-381 
CD3-PE.Cy7 (BD #563423), anti-CD4-PerCP.Cy5.5 (BioLegend #300530), anti-CD25-APC 382 
(BD #555434), anti-FoxP3-AlexaFluor488 (BD #560047) and anti-IL-10-PE (eBioscience #12-383 
7108).  384 
 385 
Flow cytometry was performed on BD Fortessa cell analyzer and analyzed using FlowJo 386 
software (TreeStar). Cells were gated to identify the lymphocyte population based on forward 387 
and side scatter, followed by gating for single color and live cell populations. Fluorescence 388 
minus one (FMO) was used for gating. Unstained, single color and fluorescence-minus-one 389 
controls were used to identify stained populations. For T lymphocyte suppression assay, control 390 
CD4+ CD25+ lymphocytes were sorted from PBMC cultures incubated with extracts from 391 
unrelated control or MS spore-forming bacteria in Treg-differentiating conditions on Aria III cell 392 
sorter (BD Biosciences) and cultured with CD4+ CD25- from the same donor pre-loaded with a 393 
CFSE cell division tracker kit. Statistical significance of expression changes in markers of T 394 
lymphocyte differentiation and proliferation was determined using two-tailed Student’s t test to 395 
compare samples from different donors and two-tailed repeated measures t test to compare 396 
samples from the same donor. GraphPad Prism 6 software was used to analyze and plot the data. 397 
P < 0.05 was considered statistically significant. 398 
 399 
Data availability: 400 
All 16S amplicon sequencing data presented in this article are available from the corresponding 401 
author upon request.   402 
  403 
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Figure Legends 544 
 545 
Figure 1. Differences in community composition of spore-forming bacterial fraction in MS 546 
patients and healthy controls. A-C.  Comparison of microbial community composition of 547 
spore-forming bacterial subset and total stool bacteria in untreated MS patients (n=25) and 548 
controls (n=24). A. Chao1 metric of alpha diversity. B. Median and range of distances 549 
(unweighted Unifrac distance matrix) within and between sample groups. C. Mean relative 550 
abundance of microbial genera. D-F. Comparison of relative abundances of individual microbial 551 
taxa in untreated MS patients (n=25) and controls (n=24). D.  Volcano plot of relative abundance 552 
distribution of microbial OTUs. X axis, log2 fold of relative abundance ratio between MS 553 
patients and controls after variance-stabilizing transformation. Y axis, negative log10 of P value, 554 
negative binomial Wald test, Benjamini-Hochberg correction for multiple comparisons. E, F.  555 
Relative abundances of bacterial classes Bacilli (E) and Clostridia (F) within phylum Firmicutes 556 
out of spore-forming bacteria from controls and MS patients. Error bars, mean +/- SEM. CTRL, 557 
total stool bacteria from controls. CTRL_spore, spore-forming bacteria from controls. MS, total 558 
stool bacteria from MS patients. MS_spore, spore-forming bacteria from MS patients.  559 
 560 
Figure 2. Spore-forming bacteria from MS patients inhibit IL-10+ Treg differentiation in 561 
vitro. A, B.  Representative flow cytometry plots (A) and quantification (B) of CD4+FoxP3+ 562 
Tregs within CD3+ lymphocytes differentiated in response to spore-forming bacteria isolated 563 
from controls or untreated MS patients. N = 7 PBMC donors; each dot represents an average 564 
response from PBMC donor to isolates from 6 control or MS bacteria donors. **P<0.01, two-565 
tailed repeated measures t test. C, D. Representative flow cytometry plots (C) and quantification 566 
(D) of IL-10+ lymphocyte population within CD3+CD4+FoxP3+ Tregs differentiated in 567 
response to spore-forming bacteria isolated from controls or untreated MS patients. N = 6 568 
bacteria donors per group. *P<0.05, two-tailed t test. Error bars, mean +/- SEM. Experiment was 569 
repeated with non-overlapping PBMC and bacterial donors and gave the same results. E. 570 
Quantification of T effector cell proliferation in response to Tregs differentiated in presence of 571 
spore-forming bacteria from MS patients or controls. N = 3 bacterial donors per group, each 572 
representing an average of 3 technical replicates. F Linear correlation between IL-10+ 573 
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population within CD3+ CD4+ FoxP3+ Tregs and Clostridia-Bacilli relative abundances.  R
2 
= 574 
0.214, p = 0.0459. Red dots, MS patients. Blue dots, controls. R^2 = 0.214, p = 0.046.  575 
 576 
Figure 3. Spore-forming bacteria composition is correlated with T lymphocyte phenotypes 577 
in vivo. A. Clinical EAE scores of mice that after antibiotic treatment had been colonized with 578 
spore-forming bacteria from controls (CTRL_spore) or MS patients (MS_spore) for 2 weeks, or 579 
kept on antibiotics (ABX) or in SPF condition as controls, prior to induction of EAE at 9-10 580 
weeks of age. N = 5-10 mice per group. B, C. Principal coordinate plot of beta diversity (PCoA; 581 
unweighted Unifrac) (B) and genus-level taxonomical distribution (C) of mouse fecal microbiota 582 
at 2 weeks of colonization with spore-forming bacteria, 2 separate experiments. D. Bacterial 583 
genera whose abundance is correlated with changes in immune cell differentiation in gnotobiotic 584 
mice are shown. The linear correlation between relative abundances of bacterial genera and the 585 
percentage of IL-10+ regulatory and IFN+ Th1 out of CD4+ Th lymphocytes from both spleens 586 
and mesenteric lymph nodes (MLN) of mice colonized with spore-forming bacteria are depicted 587 
as a heatmap. Same samples as in B-C. Only the genera that show significant linear correlation 588 
with immune parameters (p>0.05 after Benjamini-Hochberg adjustment for multiple 589 
comparisons) are included in the heat map. Red rectangle, putative pro-inflammatory subset. 590 
Blue rectangle, putative anti-inflammatory subset. Red font, taxa significantly increased in mice 591 
colonized with spore-forming bacteria from MS patients compared to controls. Blue font, taxa 592 
significantly reduced in mice colonized with spore-forming bacteria from MS patients compared 593 
to controls. E. Examples of positive and negative correlation between bacteria and Th 594 
lymphocyte differentiation from D.  595 
 596 
Figure 4. Increased Akkermansia is linked with MS-associated changes in spore-forming 597 
bacteria and pro-inflammatory T lymphocytes. A. Principal coordinate plot of beta diversity 598 
(PCoA; unweighted Unifrac) of mouse fecal microbiota excluding Akkermansia at 2 weeks of 599 
colonization with spore-forming bacteria, 2 separate experiments, colored by Akkermansia 600 
presence (red to green: low to high). p < 0.001, significant contribution of Akkermansia presence 601 
to determining distance variation (adonis method for continuous variables). B. Relative 602 
abundance of Akkermansia in controls and MS patients used for isolation of spore-forming 603 
bacteria. p = 1.5E-09, negative binomial Wald test, Benjamini-Hochberg correction for multiple 604 
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comparisons (across all 144 species detected in the dataset). C. Linear correlation of relative 605 
abundance of Akkermansia with IFN+ Th1 lymphocyte differentiation in spleens of mice 606 
colonized with spore-forming bacteria. R^2 = 0.18, p= 0.0003. D. Bacterial genera significantly 607 
correlated with Akkermansia in vivo.  608 
 609 
 610 
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Supplementary Material 612 
 613 
Supplementary Table 1. Spore-forming OTUs that were significantly different between MS 614 
patients and controls. Negative binomial Wald test with Benjamini-Hochberg correction for 615 
multiple comparisons. 616 
 617 
Supplementary Table 2. Genera that were significantly different between antibiotic-treated 618 
mice colonized with spore-forming bacteria from MS patients and controls. Negative 619 
binomial Wald test with Benjamini-Hochberg correction for multiple comparisons. 620 
 621 
Supplementary Table 3. OTUs that were significantly different between antibiotic-treated 622 
mice colonized with spore-forming bacteria from MS patients and controls. Negative 623 
binomial Wald test with Benjamini-Hochberg correction for multiple comparisons. 624 
 625 
 626 
Supplementary Figure 1. Relative abundance of Clostridium perfringens OTUs in spore-627 
forming bacteria of MS patients and controls. N=30 patients, 24 controls. X axis, OTU IDs 628 
taken from GreenGenes 13.8 database. Y axis, relative abundances after rarefaction to 10,000 629 
reads/sample. Last two columns (highlighted on graph) represent the sum of all individual OTUs.  630 
 631 
 632 
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Table 1. Subject characteristics 
Feature Cases Controls 
n 25 24 
Proportion female (%) 80.0% 12.5% 
Mean age (years [stdev]) 44.0 (±13.0) 49.3 (±12.0) 
Average BMI (stdev) 23.8 (±4.7) 24.2 (±4.2) 
Average disease duration (Years [stdev]) 13.5 (±11.9) N/A 
Proportion Off-therapy  28% N/A 
Proportion therapy naïve 72% N/A 
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